Causes of haloperidol discontinuation in patients with Tourette's disorder: Management and alternatives

Journal of Clinical Psychiatry

Volumn 57, Issue 3, 1996, Pages 129-135

  Silva, Raul R ^a,b   Muñoz, Dinohra M ^a   Daniel, Will ^a   Barickman, Julia ^a   Friedhoff, Arnold J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLONIDINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; PIMOZIDE; PROPRANOLOL; TRIHEXYPHENIDYL;

ADOLESCENT; ADULT; AKATHISIA; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; DOSE RESPONSE; DYSPHORIA; DYSURIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERACTIVITY; IMPOTENCE; LETHARGY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER; TARDIVE DYSKINESIA; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AFFECT; AFFECTIVE SYMPTOMS; AGE OF ONSET; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEAR; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; PATIENT EDUCATION; PSYCHIATRIC STATUS RATING SCALES; TOURETTE SYNDROME; TREATMENT REFUSAL;

EID: 0029990103     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Shapiro AK, Shapiro E. Tourette syndrome: clinical aspects, treatment, and etiology. Semin Neurol 1982;2:373-385
2. Fulton WA, Shady GA, Champion LM. An evaluation of Tourette syndrome and medication use in Canada. Neurosci Biobehav Rev 1988;12:251-254
3. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 1983; 40:1235-1240
4. Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette syndrome. J Am Acad Child Psychiatry 1984;23:161-173
5. Mesulam M-M, Petersen RC. Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. Neurology 1987;37:1828-1833
6. Campbell M, Silva RR, Kafantaris V, et al. Predictors of side effects associated with lithium administration in children. Psychopharmacol Bull 1991;27:373-380
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
8. Jagger J, Prusoff BA, Cohen DJ, et al. The epidemiology of Tourette's syndrome. Schizophr Bull 1982;8:267-278
9. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, NY: John Wiley; 1988:55-78
10. Physicians'Desk Reference. Oradell, NJ Medical Economics; 1991
11. Young JG, Leven LI, Knott PJ, et al. Tourette's syndrome and tic disorders. In: Weiner J, ed. Textbook of Child and Adolescent Psychiatry. New York, NY: Basic Books; 1984:216-247
12. Fulton WA. Intermittent medication cessation in the treatment of Tourette syndrome. Neurosci Biobehav Rev 1988;12:235-240
13. Leckman JF, Detlor J, Harcherik DF, et al. Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perceptive. Neurology 1985;35:343-351
14. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87-92
15. Sleator EK. Deleterious effects of drugs used for hyperactivity on patients with Gilles de la Tourette syndrome. Clin Pediatr (Phila) 1980;19:453-454
16. Riddle M, Lynch K, Scahill L, et al. Methylphenidate discontinuation and re-initiation during long-term treatment of children with Tourette's disorder and attention-deficit hyperactivity disorder (ADHD). In: Scientific Proceedings of the 40th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; May 1993; San Antonio, Tex, vol 9:61
17. Castellanos FX, Rapoport JHL, Ritchie G, et al. Stimulant treatment in children with Tourette's and ADHD. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 24, 1993; San Francisco, Calif. Abstract NR112:87
18. Sverd J, Gadow KD, Nolan EE, et al. Methylphenidate in hyperactive boys with comorbid tic disorder. In: Chase TN, Friedhoff AJ, Cohen DJ, eds. Advances in Neurology. New York, NY: Raven Press; 1992:271-281
19. Gelenberg AJ. Psychoses. In: Bassuk EL, Gelenberg AJ, eds. The Practitioner's Guide to Psychoactive Drugs. 2nd ed. New York, NY: Plenum Medical Book; 1983:11-165
20. Adler LA, Reiter S, Corwin J, et al. Differential effects of benztropine and propranolol in akathisia. Psychopharmacol Bull 1987;23:519-521
21. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988;145:621-624
22. Borison RL, Ang L, Hamilton WJ, et al. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 1983;2:205-208
23. Gualtieri CT, Quade D, Hicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984,141:20-23
24. Silva RR, Friedhoff AJ, Alpen M. Neuroleptic withdrawal-induced supersensitivity psychosis in Tourette's disorder. Biol Psychiatry 1993;34:341-342
25. Kerbeshian J, Burd L. A clinical pharmacological approach to treating Tourette syndrome in children and adolescents. Neurosci Biobehav Rev 1988;12:241-245
26. Lutz EG. Alternative drug treatment in Gilles de la Tourette syndrome. Am J Psychiatry 1977;134:99-100
27. LeWitt PA. Therapeutics of Tourette syndrome: new medication approaches. In: Chase TN, Friedhoff AJ, Cohen DJ, eds. Advances in Neurology. New York, NY: Raven Press; 1992:263-270
28. Cheng Y, Jiang DH Therapeutic effects of inosine in Tourette syndrome and its possible mechanism of action. Chung-Hua Shen Ching Ching Shen Ko Tsa Chih 1990;23:90-93,126-127
29. Friedhoff AJ. A strategy for developing novel drugs for the treatment of schizophrenia. Sehizophr Bull 1983;9:555-561
30. Friedhoff AJ, Miller JC. Clinical implications of receptor sensitivity modification. Ann Rev Neurosci 1983;6:121-148
31. Huk SG. Transient exacerbation of tics in treatment of Tourette's syndrome with clonidine. J Am Acad Child Adolesc Psychiatry 1989;28:583-586
32. Silva RR, Magee HJ, Fnedhoff AJ. Persistent tardive dyskinesia and other neuroleptic related dyskinesias in Tourette's disorder. J Child Adolesc Psychopharmacol 1993;3:137-144